Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study

Autores
Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; Elias Rodriguez, Fanny Elizabeth; Calderón, José; Arellano, Arturo; Pomata, Santiago; Rey, María Verónica; Pérez Lloret, Santiago
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background and Objectives The first weeks of treatment with antipsychotics are important for the development of their long-term efficacy. The objective of this study was to identify factors related to early clinical effects and quality of life (QoL) improvements with quetiapine extended-release (XR). Methods Six hundred and sixty-five patients starting with quetiapine XR were followed up for 8 weeks (schizophrenia = 153, major depression = 200, bipolar depression = 252, other psychiatric conditions = 60). Clinical effects were assessed by the Clinical Global Impression of Change scale (CGI-C), QoL by the visual analog scale (VAS) of the EQ-5D (QoL-VAS), and adherence by the Moriksy scale. Adverse events were explored: movement disorders by the UKU and Simpson-Angus scales, weight gain by calibrated balances, and diurnal somnolence by the Epworth Somnolence Scale (ESS). Results The mean dose of quetiapine XR during follow-up was 195.6 ± 154.8 mg/day. CGI and QoL-VAS scores improved significantly at week 8 by 2.7 ± 0.1 points and 25.1 ± 0.9 points. Adverse events were observed in 34 and 26 % of patients at weeks 4 and 8, respectively. A significant reduction in ESS score was also observed at week 8. Factors independently associated with change in QoL-VAS ≥20 points (n = 292, 43 %) were female gender, more severe disease at baseline, higher antipsychotic dose during follow-up, and improvements in somnolence. Factors independently associated with clinically significant improvement (CGI-C ≥5, n = 610, 93 %) were greater change in QoL-VAS, less frequent movement disorders at baseline, and lack of adverse events during follow-up, especially somnolence. Conclusions Results from this real-setting, large observational study in Central America suggest that disease severity at baseline, gender, antipsychotic dose, and occurrence of adverse reactions has a significant impact on the early clinical effects of quetiapine XR.
Fil: Molina, Luis. Clínica de Especialidades Altamira; Nicaragua
Fil: Recinos, Byron. Universidad San Carlos de Guatemala; Guatemala
Fil: Paz, Bezner. Hospital Juan de Dios de San Pedro; Honduras
Fil: Rovelo, Mauricio. Instituto de Salud Mental; Honduras
Fil: Elias Rodriguez, Fanny Elizabeth. Colonia Médica; El Salvador
Fil: Calderón, José. Clínica de la Conducta; Panamá
Fil: Arellano, Arturo. Corporación Farmacéutica Recalcine; Costa Rica
Fil: Pomata, Santiago. Corporación Farmacéutica Recalcine; Costa Rica
Fil: Rey, María Verónica. Etymos Consulting Group; Argentina
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
Materia
Ezquisofrenia
Depresion
Quetipina
Efectos Tempranos
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/41808
Acceder
id CONICETDig_840debfa15a6d75bb0e653dda149958f
oai_identifier_str oai:ri.conicet.gov.ar:11336/41808
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational StudyMolina, LuisRecinos, ByronPaz, BeznerRovelo, MauricioElias Rodriguez, Fanny ElizabethCalderón, JoséArellano, ArturoPomata, SantiagoRey, María VerónicaPérez Lloret, SantiagoEzquisofreniaDepresionQuetipinaEfectos Tempranoshttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background and Objectives The first weeks of treatment with antipsychotics are important for the development of their long-term efficacy. The objective of this study was to identify factors related to early clinical effects and quality of life (QoL) improvements with quetiapine extended-release (XR). Methods Six hundred and sixty-five patients starting with quetiapine XR were followed up for 8 weeks (schizophrenia = 153, major depression = 200, bipolar depression = 252, other psychiatric conditions = 60). Clinical effects were assessed by the Clinical Global Impression of Change scale (CGI-C), QoL by the visual analog scale (VAS) of the EQ-5D (QoL-VAS), and adherence by the Moriksy scale. Adverse events were explored: movement disorders by the UKU and Simpson-Angus scales, weight gain by calibrated balances, and diurnal somnolence by the Epworth Somnolence Scale (ESS). Results The mean dose of quetiapine XR during follow-up was 195.6 ± 154.8 mg/day. CGI and QoL-VAS scores improved significantly at week 8 by 2.7 ± 0.1 points and 25.1 ± 0.9 points. Adverse events were observed in 34 and 26 % of patients at weeks 4 and 8, respectively. A significant reduction in ESS score was also observed at week 8. Factors independently associated with change in QoL-VAS ≥20 points (n = 292, 43 %) were female gender, more severe disease at baseline, higher antipsychotic dose during follow-up, and improvements in somnolence. Factors independently associated with clinically significant improvement (CGI-C ≥5, n = 610, 93 %) were greater change in QoL-VAS, less frequent movement disorders at baseline, and lack of adverse events during follow-up, especially somnolence. Conclusions Results from this real-setting, large observational study in Central America suggest that disease severity at baseline, gender, antipsychotic dose, and occurrence of adverse reactions has a significant impact on the early clinical effects of quetiapine XR.Fil: Molina, Luis. Clínica de Especialidades Altamira; NicaraguaFil: Recinos, Byron. Universidad San Carlos de Guatemala; GuatemalaFil: Paz, Bezner. Hospital Juan de Dios de San Pedro; HondurasFil: Rovelo, Mauricio. Instituto de Salud Mental; HondurasFil: Elias Rodriguez, Fanny Elizabeth. Colonia Médica; El SalvadorFil: Calderón, José. Clínica de la Conducta; PanamáFil: Arellano, Arturo. Corporación Farmacéutica Recalcine; Costa RicaFil: Pomata, Santiago. Corporación Farmacéutica Recalcine; Costa RicaFil: Rey, María Verónica. Etymos Consulting Group; ArgentinaFil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; ArgentinaSpringer2016-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/41808Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; Elias Rodriguez, Fanny Elizabeth; et al.; Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study; Springer; Clinical Drug Investigation; 36; 6; 3-2016; 491-4971173-2563CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs40261-016-0395-xinfo:eu-repo/semantics/altIdentifier/doi/10.1007/s40261-016-0395-xinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-08-25T14:40:53Zoai:ri.conicet.gov.ar:11336/41808instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-08-25 14:40:54.089CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
title Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
spellingShingle Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
Molina, Luis
Ezquisofrenia
Depresion
Quetipina
Efectos Tempranos
title_short Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
title_full Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
title_fullStr Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
title_full_unstemmed Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
title_sort Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
dc.creator.none.fl_str_mv Molina, Luis
Recinos, Byron
Paz, Bezner
Rovelo, Mauricio
Elias Rodriguez, Fanny Elizabeth
Calderón, José
Arellano, Arturo
Pomata, Santiago
Rey, María Verónica
Pérez Lloret, Santiago
author Molina, Luis
author_facet Molina, Luis
Recinos, Byron
Paz, Bezner
Rovelo, Mauricio
Elias Rodriguez, Fanny Elizabeth
Calderón, José
Arellano, Arturo
Pomata, Santiago
Rey, María Verónica
Pérez Lloret, Santiago
author_role author
author2 Recinos, Byron
Paz, Bezner
Rovelo, Mauricio
Elias Rodriguez, Fanny Elizabeth
Calderón, José
Arellano, Arturo
Pomata, Santiago
Rey, María Verónica
Pérez Lloret, Santiago
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ezquisofrenia
Depresion
Quetipina
Efectos Tempranos
topic Ezquisofrenia
Depresion
Quetipina
Efectos Tempranos
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background and Objectives The first weeks of treatment with antipsychotics are important for the development of their long-term efficacy. The objective of this study was to identify factors related to early clinical effects and quality of life (QoL) improvements with quetiapine extended-release (XR). Methods Six hundred and sixty-five patients starting with quetiapine XR were followed up for 8 weeks (schizophrenia = 153, major depression = 200, bipolar depression = 252, other psychiatric conditions = 60). Clinical effects were assessed by the Clinical Global Impression of Change scale (CGI-C), QoL by the visual analog scale (VAS) of the EQ-5D (QoL-VAS), and adherence by the Moriksy scale. Adverse events were explored: movement disorders by the UKU and Simpson-Angus scales, weight gain by calibrated balances, and diurnal somnolence by the Epworth Somnolence Scale (ESS). Results The mean dose of quetiapine XR during follow-up was 195.6 ± 154.8 mg/day. CGI and QoL-VAS scores improved significantly at week 8 by 2.7 ± 0.1 points and 25.1 ± 0.9 points. Adverse events were observed in 34 and 26 % of patients at weeks 4 and 8, respectively. A significant reduction in ESS score was also observed at week 8. Factors independently associated with change in QoL-VAS ≥20 points (n = 292, 43 %) were female gender, more severe disease at baseline, higher antipsychotic dose during follow-up, and improvements in somnolence. Factors independently associated with clinically significant improvement (CGI-C ≥5, n = 610, 93 %) were greater change in QoL-VAS, less frequent movement disorders at baseline, and lack of adverse events during follow-up, especially somnolence. Conclusions Results from this real-setting, large observational study in Central America suggest that disease severity at baseline, gender, antipsychotic dose, and occurrence of adverse reactions has a significant impact on the early clinical effects of quetiapine XR.
Fil: Molina, Luis. Clínica de Especialidades Altamira; Nicaragua
Fil: Recinos, Byron. Universidad San Carlos de Guatemala; Guatemala
Fil: Paz, Bezner. Hospital Juan de Dios de San Pedro; Honduras
Fil: Rovelo, Mauricio. Instituto de Salud Mental; Honduras
Fil: Elias Rodriguez, Fanny Elizabeth. Colonia Médica; El Salvador
Fil: Calderón, José. Clínica de la Conducta; Panamá
Fil: Arellano, Arturo. Corporación Farmacéutica Recalcine; Costa Rica
Fil: Pomata, Santiago. Corporación Farmacéutica Recalcine; Costa Rica
Fil: Rey, María Verónica. Etymos Consulting Group; Argentina
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
description Background and Objectives The first weeks of treatment with antipsychotics are important for the development of their long-term efficacy. The objective of this study was to identify factors related to early clinical effects and quality of life (QoL) improvements with quetiapine extended-release (XR). Methods Six hundred and sixty-five patients starting with quetiapine XR were followed up for 8 weeks (schizophrenia = 153, major depression = 200, bipolar depression = 252, other psychiatric conditions = 60). Clinical effects were assessed by the Clinical Global Impression of Change scale (CGI-C), QoL by the visual analog scale (VAS) of the EQ-5D (QoL-VAS), and adherence by the Moriksy scale. Adverse events were explored: movement disorders by the UKU and Simpson-Angus scales, weight gain by calibrated balances, and diurnal somnolence by the Epworth Somnolence Scale (ESS). Results The mean dose of quetiapine XR during follow-up was 195.6 ± 154.8 mg/day. CGI and QoL-VAS scores improved significantly at week 8 by 2.7 ± 0.1 points and 25.1 ± 0.9 points. Adverse events were observed in 34 and 26 % of patients at weeks 4 and 8, respectively. A significant reduction in ESS score was also observed at week 8. Factors independently associated with change in QoL-VAS ≥20 points (n = 292, 43 %) were female gender, more severe disease at baseline, higher antipsychotic dose during follow-up, and improvements in somnolence. Factors independently associated with clinically significant improvement (CGI-C ≥5, n = 610, 93 %) were greater change in QoL-VAS, less frequent movement disorders at baseline, and lack of adverse events during follow-up, especially somnolence. Conclusions Results from this real-setting, large observational study in Central America suggest that disease severity at baseline, gender, antipsychotic dose, and occurrence of adverse reactions has a significant impact on the early clinical effects of quetiapine XR.
publishDate 2016
dc.date.none.fl_str_mv 2016-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/41808
Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; Elias Rodriguez, Fanny Elizabeth; et al.; Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study; Springer; Clinical Drug Investigation; 36; 6; 3-2016; 491-497
1173-2563
CONICET Digital
CONICET
url http://hdl.handle.net/11336/41808
identifier_str_mv Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; Elias Rodriguez, Fanny Elizabeth; et al.; Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study; Springer; Clinical Drug Investigation; 36; 6; 3-2016; 491-497
1173-2563
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs40261-016-0395-x
info:eu-repo/semantics/altIdentifier/doi/10.1007/s40261-016-0395-x
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1874774458688864256
score 13.265058

Publicaciones similares